Biotechnology company Stoke Therapeutics recently disclosed a key timeline for its R&D pipeline.

The highly anticipated data from the pivotal Phase III clinical trial is expected to yield final results in the third quarter of 2027. Subsequently, the company plans to complete the submission of its new drug application (NDA) to regulatory authorities in the second half of 2027. This progress marks a critical step toward commercializing the company's investigational therapy. Market analysts are closely watching the performance of data at this time point, as it will directly impact the approval prospects of the therapy and the company's future market valuation. Investors will closely follow further developments.